

# Genetic association study of age-related macular degeneration in the Spanish population

María Brión,<sup>1,2</sup> Manuel Sanchez-Salorio,<sup>3</sup> Marta Cortón,<sup>2</sup> Maria de la Fuente,<sup>3</sup> Belen Pazos,<sup>3</sup> Mohammad Othman,<sup>4</sup> Anand Swaroop,<sup>4,5</sup> Goncalo Abecasis,<sup>6</sup> Beatriz Sobrino<sup>2,7</sup> and Angel Carracedo<sup>2,7</sup> for the Spanish multi-centre group of AMD

<sup>1</sup>Genetics of Cardiovascular and Ophthalmologic Diseases, Hospital-University Complex of Santiago (CHUS), Santiago de Compostela, Spain

<sup>2</sup>Genomics Medicine Group, University of Santiago de Compostela, CIBERER Santiago de Compostela, Spain

<sup>3</sup>Instituto Gallego de Oftalmología (INGO), Santiago de Compostela, Spain

<sup>4</sup>Departments of Ophthalmology and Visual Sciences and Human Genetics, University of Michigan, Ann Arbor, Michigan, USA

<sup>5</sup>Neurobiology, Neurodegeneration & Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA

<sup>6</sup>Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, Minnesota, USA

<sup>7</sup>National Genotyping Center (CEGEN), University of Santiago de Compostela, Santiago de Compostela, Spain

## ABSTRACT.

**Purpose:** To investigate new genetic risk factors and replicate reported associations with advanced age-related macular degeneration (AMD) in a prospective case-control study developed with a Spanish cohort.

**Methods:** Three hundred and fifty-three unrelated patients with advanced AMD (225 with atrophic AMD, 57 with neovascular AMD, and 71 with mixed AMD) and 282 age-matched controls were included. Functional and tagging SNPs in 55 candidate genes were genotyped using the SNPlex™ genotyping system. Single SNP and haplotype association analysis were performed to determine possible genetic associations; interaction effects between SNPs were also investigated.

**Results:** In agreement with previous reports, *ARMS2* and *CFH* genes were strongly associated with AMD in the studied Spanish population. Moreover, both loci influenced risk independently giving support to different pathways implicated in AMD pathogenesis. No evidence for association of advanced AMD with other previous reported susceptibility genes, such as *CST3*, *CX3CR1*, *FBLN5*, *HMCN1*, *PON1*, *SOD2*, *TLR4*, *VEGF* and *VLDLR*, was detected. However, two additional genes appear to be candidate markers for the development of advanced AMD. A variant located at the 3' UTR of the *FGF2* gene (rs6820411) was highly associated with atrophic AMD, and the functional SNP rs3112831 at *ABCA4* showed a marginal association with the disease.

**Conclusion:** We performed a large gene association study in advanced AMD in a Spanish population. Our findings show that *CFH* and *ARMS2* genes seem to be the principal risk loci contributing independently to AMD in our cohort. We report new significant associations that could also influence the development of advanced AMD. These findings should be confirmed in further studies with larger cohorts.

**Key words:** *ABCA4* – age-related macular degeneration – *ARMS2* – case-control study – *CFH* – *FGF2* – genetic association

Acta Ophthalmol. 2011; 89: e12–e22

© 2010 The Authors

Acta Ophthalmologica © 2010 Acta Ophthalmologica Scandinavica Foundation

doi: 10.1111/j.1755-3768.2010.02040.x

## Introduction

Age-related macular degeneration (AMD) is a late-onset, genetically complex disease that causes progressive damage to the macula. Early stages are characterized by the presence of small, intermediate or soft drusen and pigmentary abnormalities in the retinal pigment epithelium (RPE). Progression to advanced stage leads to loss of central vision after the development of two different types of late-stage lesions, choroidal neovascularization (CNV), associated with sub-retinal haemorrhage and scarring; or geographic atrophy (GA). Advanced AMD is the major cause of untreatable blindness in the Western countries (Friedman et al. 2004). Although neovascular AMD accounts for about 10% of AMD cases, it is responsible for more than 90% of legal blindness due to AMD (Jager et al. 2008).

Several environmental, dietary, and genetic risk factors have been established for AMD development, including age, Caucasian race, heredity, and

smoking history (Seddon et al. 1997; van Leeuwen et al. 2003). Smoking has been consistently established as a risk factor, resulting in about two- to three-fold increased risk of developing AMD in current-smokers compared with never-smokers (Thornton et al. 2005).

In recent years, major progress has been made in elucidating the AMD genetic basis through the identification of two major risk loci at 1q31 and 10q26, together accounting for above 50% of AMD cases (Edwards et al. 2005; Klein et al. 2005). At 1q31, several risk variants and haplotypes in the complement factor H (*CFH*) gene have been strongly associated with early and advanced AMD, suggesting an involvement of immune-mediated complement pathway in AMD pathogenesis (Edwards et al. 2005; Hageman et al. 2005, 2006; Klein et al. 2005; Hughes et al. 2006; Li et al. 2006). In addition, several complement genes have recently been also associated with AMD susceptibility, including complement factor B (*CFB*), complement 2 (*C2*), and complement 3 (*C3*) genes (Gold et al. 2006; Maller et al. 2007; Yates et al. 2007). Besides the complement pathway, the major genetics contributor to AMD risk lies in 10q26 locus at *ARMS2/HTRA1* genes. Variants in this region have been consistently reproducible across multiple ethnic groups (Jakobsdottir et al. 2005; Rivera et al. 2005; Dewan et al. 2006; Schmidt et al. 2006; Tanimoto et al. 2007; Weger et al. 2007). To date, many candidate gene association studies have been carried out, describing several other minor susceptibility variants. However, those findings should be considered as inconclusive because of the lack of consistent replication in different populations (Swaroop et al. 2009). Despite this progress in AMD genetic research in the past few years, the total number of loci involved in AMD development and their account for the population attributable risk are far from being fully known. Identification of these genetic and environmental risk factors is the first step towards earlier detection, prevention, and in the future, better treatments.

To further investigate the genetic complexity of advanced AMD in Spain, we performed a large and comprehensive study of candidate genes for advanced AMD, including 350

functional and tagging variants in 55 genes. Our aim was to identify new genetic risk factors, and to replicate the two major and other minor AMD risk loci previously reported. We additionally aimed to explore the combined effects and potential interactions between gene variants.

## Materials and Methods

### Patient population

A total of 353 case subjects with advanced AMD and 282 age-matched unrelated controls were recruited from ophthalmic clinics in fifteen hospitals from the Spanish multi-centre group of AMD. Subjects were all Caucasian and of Spanish descent.

The diagnosis of AMD was established on the basis of 35° colour pictures obtained of the macular area of each eye, after dilatation of pupils with tropicamide 0.5% and phenylephrine 5%. Fundus photographs were graded according to the Age-Related Eye Disease Study (AREDS) classification for AMD by two trained professionals (Age-Related Eye Disease Study Research Group 2000). AMD patients were categorized into early and advanced AMD, according to status in the more severely affected eye. Briefly, early AMD (grades 2 and 3) was defined as the presence of either soft, distinct drusen with pigmentary irregularities, or soft, indistinct drusen with or without pigmentary irregularities. Advanced AMD (grade 4) was defined as atrophic, neovascular or mixed AMD. As this study focused on end-stage disease, patients with early AMD changes were excluded. Patients were classified in three subgroups: 225 subjects with atrophic AMD, 57 subjects with neovascular AMD, and finally 71 patients with a mixed phenotype, with both geographic atrophy and choroidal neovascularization.

Age-matched controls were recruited from the same hospitals during routine ophthalmic examinations and were above 65 years of age. Control individuals had no evidence of drusen in either eye, macular or retinal disorder after ophthalmic examination, family relationship with the AMD cohort, or family history of maculopathies.

This study was conducted according to the recommendations of the Declaration of Helsinki and approved by the

local ethics committees of the participating institutions. Signed informed consent was obtained from all subjects before inclusion in the study. Each participant was given a short questionnaire about sex, smoking, refraction, medical history review, and familial history of AMD. Data on disease status, sex, age, and smoking history of subjects are provided in Table 1.

### Candidate genes and SNPs selection

Fifty-five candidate genes were selected on the basis of biological and genetics knowledge of AMD. We included genes involved in AMD pathogenic mechanisms, such as oxidative damage, chronic inflammation, complement regulation, RPE or photoreceptor death and angiogenesis regulation, by previous expression, knock-out, proteomic or biochemical studies (Mullins et al. 2000; Lambouij et al. 2003; Rakic et al. 2003; Hahn et al. 2004; Martin et al. 2004). We also selected some functional candidate genes located at several loci associated with the disease by previous genome-wide linkage studies, such as 1q32, 3q24-q25, 4q27, 9q33, 12q23.2-24.31, 17q25.1, 19q13.31 (Majewski et al. 2003; Abecasis et al. 2004; Weeks et al. 2004; Fisher et al. 2005; Jun et al. 2005; Barral et al. 2006). Finally, we also studied the two major risk loci for AMD, *CFH* and *ARMS2* genes, and other putative susceptibility genes, such as *ABCA4*, *APOE*, *CST3*, *CX3CR1*, *FBLN5*, *HMCN1*, *PON1*, *SOD2*, *TLR4*, *VEGFA* and *VLDLR*. More information about the candidate genes and their selection are given in the Appendix.

Our aim was to examine common variations [Minor Allele Frequency (MAF) > 0.1] in the selected candidate genes for AMD predisposition. Single nucleotide polymorphisms (SNP) selection was based on functional variation and linkage disequilibrium (LD) data from the International HapMap Project [<http://www.hapmap.org/>] (HapMap 2003). First, we selected all known common non-synonymous coding SNPs deposited in the dbSNP database (Build 126) [<http://www.ncbi.nlm.nih.gov/SNP/index.html>]. Second, we used FESD, a functional SNP Database [<http://variome.kobic.re.kr/FESD/index.php>] in order to prioritize putative regulatory SNPs (Kang et al.

**Table 1.** Baseline characteristics of age-related macular degeneration patients and controls.

Variable	Controls (N = 282)	Cases (N = 353)	p-value
Affection status, n (%)			
No AMD	282		
Neovascular AMD		225 (63.7)	
Geographic atrophy		57 (16.2)	
Mixed AMD		71 (20.1)	
Sex, n (%)			
Male	126 (44.7)	163 (46.2)	0.707
Female	156 (55.3)	190 (53.82)	
Mean age (SD)	75.1 (5.8)	76.74 (5.82)	0.003
Smoking history, n (%)			
No. of subjects	278	344	0.134
Never smoked	209 (75.2)	240 (69.8)	
Current or former smoker	69 (24.8)	104 (30.2)	
HTA, n (%)			
No. of subjects	280	348	0.983
No	133 (47.5)	165 (47.4)	
Yes	147 (52.5)	183 (52.6)	
Diabetes mellitus, n (%)			
No. of subjects	281	348	0.874
No	241 (85.8)	300 (86.2)	
Yes	40 (14.23)	48 (13.8)	
Atheromatous disease, n (%)			
No. of subjects	280	345	
No	226 (80.7)	269 (78)	
Ischaemic cardiopathy	32 (11.4)	44 (13)	0.568
Ischaemic stroke	6 (2.1)	12 (3.6)	0.297
Peripheral atherosclerosis	27 (9.6)	33 (9.8)	0.950

2005). Finally, using genotypes and haplotypes from the HapMap Caucasian (CEU) population panel, tagSNPs were selected by using a tagging strategy with the Tagger tool implemented in Haploview (Barrett et al. 2005), using a strong LD tagging criteria of  $r^2 > 0.8$  and with MAF  $> 10\%$ . Each candidate gene was covered including an extended region of 10 kb upstream and downstream of the coding region.

**Genotyping**

Genomic DNA was isolated from peripheral blood using Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA). SNP genotyping was performed by the SNPlex™ genotyping system available in the Santiago de Compostela node of the National Genotyping Centre of Spain (CEGEN, Santiago de Compostela, Spain) (Tobler et al. 2005). Genotyping assays were successfully designed for 380 SNPs using the assay design to the SNPlex System Bioinformatics Design Pipeline. SNPlex technology uses oligonucleotide ligation assay (OLA) combined with multiplex PCR technology to achieve allelic discrimination and target amplification. The final products are detected by capil-

lary electrophoresis on 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA, USA) and analysed with GeneMapper v.4.0 (Applied Biosystems). As a quality control, we tested for any departure from Hardy–Weinberg equilibrium (HWE) in control samples ( $p > 0.001$ ).

Quality measures taken into account for genotyped SNPs to be excluded from the subsequent analysis were: MAF  $< 0.05$ , genotyping success  $< 80\%$  and failed Hardy–Weinberg equilibrium test in control samples ( $p > 0.001$ ).

**Statistical analysis**

Analyses of genotyping results were performed using several toolsets implemented in SNPator [http://www.snpator.com/] (Morcillo-Suarez et al. 2008), Haploview 4.0 [http://www.broad.mit.edu/mpg/haploview/] (Barrett et al. 2005) and SNPassoc [http://cran.r-project.org/web/packages/SNPassoc/index.html] software (Rakic et al. 2003). Mann–Whitney U test was used to compare the ages of cases subjects and controls. Chi-square test was used to compare categorical variables and allele or haplotypes frequencies between AMD patients (or in the

three AMD subgroups) and controls and to check for Hardy–Weinberg equilibrium (HWE) in control group. Fisher’s exact test was used when allele counts were  $< 5$  by convention. Likelihood ratio test was used to compare genotype frequencies and to investigate interaction effects between SNPs. Dominant, recessive and codominant models were considered and the Akaike information criteria (AIC) was used to choose the genetic model that best fits the data. Adjusted analyses by traditional risk factors of AMD (age, gender and smoking status) were done with logistic regression models. p values, odds ratios (ORs) and 95% confidence intervals are reported. To evaluate the significance of the genetic associations with AMD after adjustment for multiple testing, permutation correction was performed with the association tests of individual SNPs with 10 000 simulations (Corrected  $p < 0.05$  was considered as significant).

Linkage disequilibrium was assessed using both  $D'$  and  $r^2$  measures implemented in Haploview. Haplotype inference was performed by the EM algorithm and haplotype blocks were generated by the algorithm and parameters of Gabriel et al. (2002). Permutation test was used to adjust for multiple testing.

**Results**

We genotyped 380 SNPs in 55 candidate genes in a Spanish population of 353 patients with advanced AMD and 282 age-matched control subjects. The mean age at examination was 76.2 years for AMD patients (standard deviation [SD], 5.9 years; range, 52–96 years) and 75.1 years for controls (SD, 5.8 years; range, 65–92 years). Although patients were slightly older than controls ( $p = 0.003$ ), the other factors, such as the gender, smoking status, hypertension, diabetes mellitus, and atheromatous disease, did not differ between cases and controls.

Of the selected SNPs, 27 failed in the SNPlex Genotyping system, 14 had low genotyping call rate and 7 were monomorphic in our population. Therefore, these 48 of the 380 SNPs were not further studied. The success genotyping rate for the remaining SNPs was above 92%. These were tested separately in case and control

**Table 2.** Single marker analysis. Allele association results.

Gene	SNP	MAF	Alleles	Advanced AMD			Exudative AMD			Atrophic AMD			Mixed AMD		
				OR (95% CI)	p-value (Perm. p-value)*	OR (95% CI)	p-value (Perm. p-value)*	OR (95% CI)	p-value (Perm. p-value)*	OR (95% CI)	p-value (Perm. p-value)*				
<i>ABCA4</i>	rs3112831	0.37	A/G	1.47 (1.84-1.15)	<b>0.0015 (0.0369)</b>	1.01 (1.31-0.79)	<b>0.027 (0.6537)</b>	1.84 (2.88-1.19)	<b>0.006 (0.2428)</b>	1.58 (2.36-1.06)	<b>0.0252 (0.8171)</b>				
<i>CFH</i>	rs800292	0.154	C/T	1.68 (2.29-1.24)	<b>0.0009 (0.0374)</b>	1.73 (2.47-1.21)	<b>0.0022 (0.0091)</b>	1.01 (1.68-0.6)	0.9758	2.83 (5.41-1.47)	<b>0.0012 (0.0350)</b>				
<i>CFH</i>	rs3766404	0.133	T/C	2.21 (3.08-1.58)	<b>2.17 × 10<sup>-06</sup> (0.0001)</b>	2.12 (3.1-1.45)	<b>8.87 × 10<sup>-05</sup> (0.0043)</b>	2.62 (5.35-1.28)	<b>0.003 (0.2518)</b>	2.23 (4.1-1.21)	<b>0.0084 (0.2695)</b>				
<i>CFH</i>	rs1529421	0.44	T/A	2.04 (2.57-1.62)	<b>8.12 × 10<sup>-10</sup> (&lt;0.0001)</b>	1.87 (2.42-1.45)	<b>1.27 × 10<sup>-06</sup> (&lt;0.0001)</b>	2.19 (3.3-1.46)	<b>0.0001 (0.0076)</b>	2.34 (3.71-1.74)	<b>8.15 × 10<sup>-07</sup> (0.0002)</b>				
<i>CFH</i>	rs1831282	0.47	T/G	2 (2.52-1.6)	<b>1.86 × 10<sup>-09</sup> (&lt;0.0001)</b>	1.84 (2.37-1.43)	<b>2.23 × 10<sup>-06</sup> (&lt;0.0001)</b>	2.06 (3.1-1.37)	<b>0.0004 (0.0249)</b>	2.58 (3.77-1.76)	<b>6.79 × 10<sup>-07</sup> (0.0002)</b>				
<i>CFH</i>	rs12144939	0.183	G/T	2.35 (3.15-1.75)	<b>6.23 × 10<sup>-09</sup> (&lt;0.0001)</b>	2.33 (3.26-1.66)	<b>5.52 × 10<sup>-7</sup> (&lt;0.0001)</b>	2.89 (5.41-1.54)	<b>0.0006 (0.0323)</b>	2.07 (3.45-1.24)	<b>0.0044 (0.1890)</b>				
<i>CFH</i>	rs2284664	0.13	G/A	1.71 (2.33-1.21)	<b>0.002 (0.0395)</b>	1.83 (2.69-1.24)	<b>0.002 (0.0905)</b>	1.03 (1.77-0.6)	0.9126	2.31 (4.45-1.2)	<b>0.0102 (0.2988)</b>				
<i>CFH</i>	rs1329428	0.31s	G/A	2.49 (3.19-1.95)	<b>2.13 × 10<sup>-13</sup> (&lt;0.0001)</b>	2.65 (3.52-1.99)	<b>9.91 × 10<sup>-12</sup> (&lt;0.0001)</b>	1.96 (3.08-1.25)	<b>0.003 (0.1356)</b>	2.54 (3.94-1.64)	<b>2.11 × 10<sup>-05</sup> (0.0020)</b>				
<i>FGF2</i>	rs6820411	0.122	A/C	1.96 (2.83-1.36)	<b>0.0002 (0.0043)</b>	1.76 (2.63-1.17)	<b>0.0057 (0.092)</b>	2.63 (4.58-1.51)	<b>0.0004 (0.0144)</b>	2.13 (3.64-1.24)	<b>0.0052 (0.0977)</b>				
<i>LOC387715</i>	rs10490924	0.324	T/G	3.94 (5.14-3.02)	<b>1.75 × 10<sup>-25</sup> (&lt;0.0001)</b>	4.20 (5.61-3.15)	<b>7.46 × 10<sup>-34</sup> (&lt;0.0001)</b>	3.56 (5.49-2.31)	<b>9.12 × 10<sup>-09</sup> (&lt;0.0001)</b>	3.48 (5.19-2.33)	<b>1.07 × 10<sup>-09</sup> (&lt;0.0001)</b>				
<i>CGREF1</i>	rs2384571	0.453	C/G	1.2 (1.51-0.97)	0.0983			1.84 (2.8-1.2)	<b>0.0045 (0.0484)</b>						
<i>APOE</i>	rs7259004	0.102	C/G	1.08 (1.56-0.75)	0.6905					2.22 (3.68-1.34)	<b>0.0015 (0.0199)</b>				

OR, odds ratios.  
Perm. p value = p-value from 10 000 permutations  
\* Significant p-values (< 0.05) are shown in bold.

samples for any departure from the Hardy-Weinberg equilibrium. All the SNP were in Hardy-Weinberg equilibrium in controls samples ( $p > 0.001$ ) with the exception of two SNPs (rs968451 and rs4858652), which were also excluded from further analyses.

**Single-SNP association study**

Association analysis was directly assessed with the 330 SNPs (Appendix) and adjusted analyses by age, gender and smoking status were also performed, with similar results (data not shown). After correction for multiple hypothesis testing through permutation analysis (corrected-p < 0.05), SNPs strongly associated with advanced AMD are compiled in Tables 2 and 3. Additional stratified analyses by AMD subphenotype (neovascular, atrophic or mixed AMD) were also performed and most of the above SNPs remained statistically significant in spite of the smaller number of atrophic and mixed AMD patients

In agreement with previous reports, both *ARMS2* and *CFH* genes were associated with AMD in Spanish population (de la Fuente et al. 2007; Recalde et al. 2008). Briefly, the T risk allele in the A69S variant (rs10490924) at *ARMS2* gene showed the strongest association with late stage AMD (T allele, OR = 3.94,  $p = 1.75 \times 10^{-25}$ ; OR<sub>hom</sub> = 12.64, OR<sub>het</sub> = 4.19,  $p = 3.19 \times 10^{-21}$ ). As shown in Table 2, A69S confers similar risks to the three forms of advanced AMD. In the same way, seven alleles at *CFH* gene were also significantly associated with advanced AMD patients. Between them, two intronic tagging SNPs (rs1329428 and rs1329421) showed the strongest associations (OR = 2.49,  $p = 2.13 \times 10^{-13}$  and OR = 2.04,  $p = 8.12 \times 10^{-10}$ , respectively). When neovascular, atrophic and mixed AMD stratified analyses were performed, association with *CFH* gene remained. No epistatic interactions were detected between rs10490924 at *ARMS2* gene and the two most significant SNPs at *CFH* gene based on the likelihood ratio test (Table 4).

In addition to the previously known risk variants of AMD, a tagging SNP (rs6820411) located 3'' of *FGF2* (*Fibroblast growth factor 2*) was also associated with advanced AMD after permutation correction (allele A OR =

1.96,  $p = 0.0043$ ; OR<sub>AA+AC</sub> = 2.2,  $p = 0.0076$ ). Also, their effect remained significant after adjusting for other risk factors, including smoking status, age and polymorphisms in *CFH* and *ARMS2* (data not shown). When phenotype subgroups were compared with controls, allele and genotype frequency differences were also found. Although the association remained significant only for atrophic AMD cases after correction for multiple testing, exudative and mixed AMD cases showed a trend toward association (Table 2). Epistatic interactions were not detected between rs6820411 at *FGF2* and risk alleles in *ARMS2* and *CFH* based on the likelihood ratio test, as shown in Table 5.

In order to replicate the putative effect of *FGF2*, the associated polymorphism in Spanish population was additionally genotyped in a total of 609 AMD cases and 325 healthy Caucasian subjects from US (Swaroop). No evidence of association was found in this cohort (allele association  $p = 0.17$ ).

Additionally, two variants showed a lesser extent of association with advanced AMD after a multiple testing correction. A functional SNP at *ABCA4* gene (rs3112831) had a marginal association ( $p = 0.0015$ ) with advanced AMD. rs2384571, and a tagSNP located in *CGREF1* gene, had also shown a significant association but only for atrophic AMD patients ( $p = 0.0045$ ).

**Haplotype association analysis**

To determine whether any of the haplotypes in the candidate genes could be associated with AMD, linkage disequilibrium (LD) analysis and haplotype estimation were performed. Haplotype analysis did not detect any association in the additional candidate genes, only *CFH* and *FGF2* haplotypes showed a strong evidence of association with late AMD after correcting for multiple testing (corrected-p < 0.05). The association between the haplotype carrying risk alleles was either equal or weaker than the association at each individual SNP.

In concordance with previous reports, *CFH* region showed extensive LD in our population, as shown in Fig. 1. Except for rs800292, all SNPs at *CFH* gene were included in a large LD block. Haplotype estimation in *CFH* gene in cases and controls identified a common risk haplotype (H1) in 50% of AMD cases versus 35% of controls

**Table 3.** Single locus analysis. Genotype association results.

Gene	SNP	Model	Genotype	AMD			Wet AMD			Dry AMD			Mixed		
				OR (95% CI)	p-value (Perm. p-value)*	OR (95% CI)	p-value (Perm. p-value)*	OR (95% CI)	p-value (Perm. p-value)*	OR (95% CI)	p-value (Perm. p-value)*	OR (95% CI)	p-value (Perm. p-value)*		
ABCA4	rs3112831	Dominant	A/A	1	<b>0.0048</b> (0.0972)	1	0.67 (0.97-0.47)	<b>0.0327</b> (0.58)	1	1	1	0.67 (0.97-0.47)	<b>0.0327</b> (0.540)		
		Recessive	A/G-G/G A/A-A/G	0.64 (0.88-0.46)											
CFH	rs800292	Recessive	G/G	1.81 (2.56-1.28)	<b>0.0008</b> (0.0368)	1.88 (2.77-1.26)	<b>0.0016</b> (0.08)	0.3 (0.86-0.10)	<b>0.0098</b> (0.224)	2.91 (5.88-1.49)	<b>0.0008</b> (0.150)	2.91 (5.88-1.49)	<b>0.0008</b> (0.150)		
		Recessive	C/C	2.32 (3.33-1.59)	<b>0.00752</b> (0.0002)	2.17 (3.33-1.43)	<b>2.00 × 10<sup>-4</sup></b> ( <b>0.0049</b> )	2.94 (6.66-1.35)	<b>0.0028</b> (0.169)	2.38 (4.76-1.21)	<b>0.0065</b> (0.230)	2.38 (4.76-1.21)	<b>0.0065</b> (0.230)		
CFH	rs1329421	Codominant	A/A	1.00	<b>1.61 × 10<sup>-5</sup></b> ( <b>&lt;0.0001</b> )	1	1.82 (2.73-1.21)	<b>2.00 × 10<sup>-5</sup></b> ( <b>&lt;0.0001</b> )	1	<b>0.0015</b> (0.038)	1	1	<b>7.04 E-47</b> ( <b>0.0023</b> )		
		Recessive	A/T T/T A/A	2.13 (3.06-1.48) 3.75 (5.98-2.36)		1.82 (2.73-1.21) 3.18 (5.30-1.91)		1.92 (3.88-0.95) 4.23 (9.29-1.92)		4.87 (9.9-2.39)	<b>7.22 × 10<sup>-06</sup></b> ( <b>0.0023</b> )	4.87 (9.9-2.39)	<b>7.22 × 10<sup>-06</sup></b> ( <b>0.0023</b> )		
CFH	rs1831282	Codominant	A/G	1	<b>5.71 × 10<sup>-5</sup></b> ( <b>&lt;0.0001</b> )	1	1.79 (2.72-1.18)	<b>4.00 × 10<sup>-5</sup></b> ( <b>0.0004</b> )	1	<b>0.0014</b> (0.078)	1	1	<b>0.0120</b> (0.560)		
		Recessive	G/T T/T G/G	2.01 (2.92-1.38) 3.57 (5.61-2.28) 9.09 (25-2.94)		1.79 (2.72-1.18) 3.04 (5.00-1.85) 11.11 (50-2.56)		1.87 (3.84-0.91) 3.7 (8.12-1.69)		3.41 (7.21-1.61) 6.33 (14.24-2.82) 6.66 (50-0.9)		4.87 (9.9-2.39)	<b>7.22 × 10<sup>-06</sup></b> ( <b>0.0023</b> )		
CFH	rs12144939	Codominant	G/T	2.08 (2.94-1.44)	<b>3.87 × 10<sup>-5</sup></b> ( <b>&lt;0.0001</b> )	2.00 (2.94-1.35)	<b>1.30 × 10<sup>-6</sup></b> ( <b>&lt;0.0001</b> )	3.22 (6.25-1.59)	<b>0.0004</b> (0.0379)	1.81 (3.33-1)	<b>0.0115</b> (0.150)	1.81 (3.33-1)	<b>0.0115</b> (0.150)		
		Recessive	T/T	1		1.00		3.22 (6.25-1.59)		1		1			
CFH	rs2284664	Recessive	G/G	1.75 (2.56-1.21)	<b>0.002563</b> (0.0901)	1.88 (2.85-1.23)	<b>0.003</b> (0.082)	1.07 (2.504-0.57)	<b>0.8100</b>	2.27 (4.54-1.14)	<b>0.0120</b> (0.560)	2.27 (4.54-1.14)	<b>0.0120</b> (0.560)		
		Codominant	A/G-A/A G/G	7.14 (14.28-4) 2.1 (2.94-1.5)	<b>2.76 × 10<sup>-09</sup></b> ( <b>&lt;0.0001</b> )	8.33 (16.66-3.84) 2.27 (3.33-1.53)	<b>1.14 × 10<sup>-10</sup></b> ( <b>&lt;0.0001</b> )	4 (12.5-1.33) 1.72 (3.22-1)	<b>0.0130</b> (0.1672)	1.11 (50-2.5) 1.96 (3.44-1.1)	<b>4.71 × 10<sup>-05</sup></b> ( <b>0.0016</b> )	1.11 (50-2.5) 1.96 (3.44-1.1)	<b>4.71 × 10<sup>-05</sup></b> ( <b>0.0016</b> )		
FGF2	rs6820411	Dominant	A/A	1	<b>7.00 × 10<sup>-05</sup></b> ( <b>0.0076</b> )	1	1.97 (3.06-1.27)	<b>0.0023</b> (0.18)	1	<b>0.0005</b> (0.078)	1	1	<b>0.0095</b> (0.250)		
		Codominant	C/C A/C-A/A	2.20 (3.28-1.48)	<b>3.19 × 10<sup>-21</sup></b> ( <b>&lt;0.0001</b> )	1	2.6 (4.97-1.36) 11.52 (29.35-4.52)	<b>1.51 × 10<sup>-21</sup></b> ( <b>&lt;0.0001</b> )	<b>6.19 × 10<sup>-07</sup></b> ( <b>&lt;0.0001</b> )	2.28 (4.17-1.24) 5.08 (9.15-2.82) 8.36 (22.87-3.05)	<b>3.9 × 10<sup>-09</sup></b> ( <b>&lt;0.0001</b> )	2.28 (4.17-1.24) 5.08 (9.15-2.82) 8.36 (22.87-3.05)	<b>3.9 × 10<sup>-09</sup></b> ( <b>&lt;0.0001</b> )		
APOE	rs7259004	Dominant	C/G-G/G	0.71 (1.01-0.5)	0.0557	14.4 (30.1-6.9)		2.63 (4.76-1.47)	<b>0.0013</b> (0.1672)	1	<b>0.0019</b> (0.16)	1	<b>0.0019</b> (0.16)		
		Recessive	G/G	1.05 (1.58-0.7)	0.7959					2.54 (4.52-1.43)		2.54 (4.52-1.43)			

OR, odds ratios.  
Perm. p-value = p-value from 10 000 permutations.  
\* Significant p-values (< 0.05) are shown in bold.

(OR = 1.99, p < 10<sup>-9</sup>) and three protective haplotypes (H3, H4 and H5), as shown in Fig. 1. All of them showed a strong association with AMD in the overall dataset and in the three AMD subgroups (data not shown). The two most associated SNPs at single-marker analysis contained alleles that mainly distinguished between risk and protective haplotypes. The T allele at rs1329421 and the A allele at rs1329428 were exclusively found in the risk and protective haplotypes, respectively.

In the analysis of LD map at *FGF2* locus (Fig. 2), a small haplotype block of 2 SNPs was found upstream of the gene. Those SNPs were not associated with AMD; however, an extensive LD region was found between the 3' part of the *FGF2* gene and downstream region, comprising *NUDT6* gene. Haplotype showed six more frequent haplotypes in the analysed population and only one of them (H3) included the risk allele at rs6820411. After multiple testing correction, only this haplotype was significantly associated with AMD risk (OR = 1.83, p < 10<sup>-4</sup>).

## Discussion

We designed a functional and tagging SNP selection strategy in 55 candidate genes, selected in basis of positional criteria, their contribution to AMD aetiology, and/or their previous implication as risk variant. We determined whether common variations across the candidate genes displayed significant association with advanced AMD or their three phenotypic subgroups (neovascular, atrophic or mixed AMD) in a Spanish population.

Despite using a different set of *CFH* variants than most of the published studies, our results in Spanish population are in agreement with previous reports in other Caucasian cohorts (Hageman et al. 2005; Klein et al. 2005; Li et al. 2006; Francis et al. 2007). Seven of eight tagSNPs here studied were associated with advanced AMD. Only rs1065489, a missense variant, did not show any evidence of association, as previously reported by Hageman et al. (2005). rs1329421 and rs1329428, located in the *CFH* introns 7 and 15, respectively, exhibited the strongest association with AMD in our Spanish cohort. With the exception of rs1329421, all significant variants at

**Table 4.** Two loci analysis. CFH and LOC 387715 interactions.

	OR (95% CI)			Interaction p
	rs10490924			
	G/G	G/T	T/T	
rs1329421				
A/A	1	4.3 (8.2–2.3)	13.2 (39–4.5)	0.99871
A/T	2.3 (4–1.3)	9.1 (17–4.9)	33.1 (101.5–10.8)	
T/T	3.9 (7.9–1.9)	15 (31.7–7.1)	45.2 (362.8–5.6)	
rs1329428				
G/G	1	4.5 (7.7–2.6)	12.3 (36.8–4.1)	0.79878
A/G	0.6 (1–0.4)	2.7 (4.6–1.3)	10.7 (37.4–3.1)	
A/A	0.2 (0.6–0.1)	0.5 (1.3–0.2)	0.8 (5.12–0.13)	
rs3766404				
T/T	1	3.9 (5.8–2.5)	13 (31.7–5.4)	0.64755
C/T	0.4 (0.7–0.2)	2.6 (5.4–1.3)	5.4 (16.7–1.7)	
C/C	0.4 (3.2–0.04)	0.6 (2.4–0.2)	NA	
rs1831282				
T/T	1	3.9 (7.5–2)	10.6 (32–3.5)	0.9939
C/T	2.07 (3.7–1.2)	8.6 (16.3–4.5)	30.6 (94.8–9.8)	
C/C	3.3 (6.7–1.7)	14.1 (29.3–6.8)	52.9 (420.4–6.6)	
rs12144939				
G/G	1	3.7 (5.8–2.4)	13.8 (36.1–5.2)	0.61646
G/T	0.5 (0.8–0.3)	3 (1.5–5.8)	6.1 (18.7–2)	
T/T	0.1 (1.1–0.02)	0.41 (1.5–0.1)	0 (NA–0)	

**Table 5.** Two locus analysis. FGF2 interactions with CFH and LOC387715.

	OR (95% CI)			Interaction p
	rs6820411			
	C/C	C/A	A/A	
<i>CFH</i>				
rs1329421				
A/A	1	2.2 (4.6–1.1)	0 (0–NA)	0.500
A/T	2.1 (3.2–1.4)	3.7 (6.8–2)	3.3 (18.6–0.6)	
T/T	3.3 (5.6–2)	12.5 (37–4.2)	NA	
rs1329428				
G/G	1	2.3 (4.4–1.2)	0.6 (9.2–0.04)	0.373
A/G	0.5 (0.7–0.3)	1.1 (2.2–0.6)	1.1 (6.3–0.2)	
A/A	0.2 (0.34–0.1)	0.1 (0.5–0.02)	NA	
rs3766404				
T/T	1	1.9 (3.1–1.2)	0.7 (3.6–0.1)	0.124
C/T	0.4 (0.7–0.3)	1.1 (2.5–0.4)	NA	
C/C	0.2 (0.7–0.05)	NA	NA	
rs1831282				
T/T	1	2.1 (4.4–1)	NA	0.729
C/T	2 (3–1.33)	3.8 (7.1–2.1)	2.2 (10.2–0.5)	
C/C	3.3 (5.5–2)	10.3 (28–3.8)	NA	
rs12144939				
G/G	1	2.3 (3.9–1.4)	1.1 (6.4–0.2)	0.836
G/T	0.5 (0.7–0.3)	1.1 (2.3–0.5)	1.4 (15.6–0.1)	
T/T	0.1 (0.5–0.04)	0.1 (1.2–0.02)	NA	
<i>LOC387715</i>				
rs10490924				
G/G	1	2.5 (4.5–1.4)	2.1 (10.9–0.5)	0.858
G/T	4.1 (6.2–2.7)	8.7 (17–4.5)	NA	
T/T	14.5 (31.9–6.6)	16.1 (72.1–3.6)	NA	

*CFH* gene were previously described as associated to AMD (Hageman et al. 2005; Klein et al. 2005; Li et al. 2006; Francis et al. 2007).


The strong linkage disequilibrium present in this region makes it difficult to distinguish the causal variant of another in linkage disequilibrium with

it. Although *CFH Y402H* could play a causal role in the development of AMD, as postulated by several reports (Skerka et al. 2007; Yu et al. 2007; Ormsby et al. 2008), also other variants could increase the risk of AMD by regulating the expression of *CFH* or *CFH*-related genes located within the *RCA (Regulation of Complement Activation)* locus on chromosome 1. In our Spanish AMD cohort, we could also found a set of common susceptibility and protective haplotypes against AMD, as previously observed in other Caucasian population. Those haplotypes were defined by 7 SNPs, and two of them, T allele at rs1329421 and the A allele at rs1329428 were exclusively found in the risk and protective haplotypes, respectively.

Although we could not assess the AMD risk associated with *CFH Y402H* due to a unsuccessful genotyping assay with SNPlex platform, we could previously report a risk effect on advanced AMD in a preliminary study with 175 AMD cases and 119 controls (de la Fuente et al. 2007). When we considered only common samples analysed in both cohorts, *Y402H* variant showed a strong LD with rs1329421 and rs1831282 ( $r^2 = 0.98$  and  $0.92$ , respectively). The risk-associated C-allele of the *Y402H* variant was found to take part of the risk haplotype H1 (data not shown). Therefore, our 7-SNP haplotype seems to fit well with risk haplotypes described in other Caucasian populations.

Our results showed that significant *CFH* polymorphisms overall associate with a similar frequency with the neovascular, atrophic and mixed AMD subtypes. Neither single variants nor risk haplotype preferentially increased susceptibility to one of these 3 phenotypes. In our report, we did not include early or intermediate stages of AMD; so, whether those polymorphisms also contribute to earlier AMD phenotypes remains to be fully explored.

Our findings also confirm *ARMS2* as another principal contributor to advanced AMD risk in Spanish population (de la Fuente et al. 2007; Kanda et al. 2007; Fritsche et al. 2008; Recalde et al. 2008). In agreement with previous studies, we could not identify gene interaction between



**Fig. 1.** LD and haplotype maps of the CFH locus in this Spanish population. A schematic representation of the intron/exon structure of the CFH gene is indicated above the LD plot. Relative positions of studied SNPs are also indicated. Each box provides  $r^2$  values with darker red shades representing stronger LD. Haplotype association analysis in cases and controls were performed for the single haplotype block found at this locus. All of the haplotypes with a frequency of >1% are displayed. The estimated frequencies of the haplotype in cases and controls, ORs, 95% CI and p-values are also shown. The risk haplotype (H1) is shown in red shading, and the protective haplotypes (H3, H4 and H5) are shown in green shading. Alleles exclusively found in these risk and protective haplotypes are boxed.

CFH and ARMS2. Thus, the A69S polymorphism in ARMS2 is strongly associated with advanced AMD in an independent extent of the CFH polymorphisms.


With regard to the rest of gene variants studied here, most of them did not show allelic or genotype frequency differences between AMD cases and controls. Only rs6820411 at FGF2 gene and rs3112831 at ABCA4 gene maintained statistical significance after multiple testing correction.

Fibroblast growth factor 2 (FGF2) is a widely expressed protein with potent angiogenic activity that promotes growth and differentiation of a broad spectrum of cell types. FGF2 seem to play also an essential role in VEGF-dependent choroidal neovascularisation (Frank 1997; Browning et al. 2008). It was found in high concentration in neovascular tissue in AMD patients and up-regulated in laser-induced choroidal neovasculari-

sation (Ogata et al. 1996; Cameron et al. 2007). In our study, we found a strong association between advanced AMD and rs6820411 even after adjusting for age, sex, smoking, CFH or ARMS2 risk variants. In addition, when endophenotypes were considered, significant association with atrophic AMD was also maintained after multiple testing corrections.

rs6820411 is located downstream of FGF2 in the promoter region of NUDT6 gene, which is transcribed in the opposite direction (Fig. 2). NUDT6 transcription generates an overlapping antisense RNA (FGF-AS) implicated in the post-transcriptional regulation of FGF-2 expression and function (Baguma-Nibasheka et al. 2007). HapMap Phase II data shows a large extent of LD as the 3' FGF2/FGF-AS region, making possible that rs6820411 being in LD with a non-assayed causal variant at FGF-AS. The lack of replication in an

admixed US population with patients at early and advanced AMD stages could be reflecting a population and phenotype-dependence of this variant on AMD susceptibility. Epidemiological studies have revealed differences in the prevalence of advanced AMD among different ethnic groups with major rates in Caucasian than African and Asian individuals (Age-Related Eye Disease Study Research Group 2000). As HapMap data showed, rs6820411 is only polymorphic in Caucasian (CEU) population. In addition, despite showing positive association with general AMD in our study, when subclinical forms of the disease were considered, the putative risk allele was only detected in the atrophic forms. Consequently, further resequencing and association analyses of FGF2/FGF-AS region in a larger cohort, phenotypically well characterized in the different clinical AMD phenotypes, are needed to confirm the



**Fig. 2.** LD and haplotype maps of the FGF2 locus in this Spanish population. A schematic representation of the intron/exon structure of the FGF2 and NUDT6 genes with the relative positions of tagSNPs, is indicated above the LD plot. Each box provides  $r^2$  values with darker red shades representing stronger LD. Haplotype association analysis in cases and controls are also performed on the two haplotype blocks found at this locus. All of the haplotypes with a frequency of >1% are displayed. The estimated haplotypic frequencies in cases and controls, p-values, ORs and 95% CI are also shown. The risk haplotype (H3) is shown in red shading remarking in a box the risk allele at rs6820411.

putative role of *FGF-AS* in AMD susceptibility.

*ABCA4* is the retina-specific ABC transporter gene and responsible for the Stargardt disease, an autosomal recessive form of juvenile macular degeneration. We observed a marginal allelic association with the missense *H423R* variant (rs3112831) with advanced AMD. Although some authors reported mutations in *ABCA4*

gene in a small percentage of AMD cases (Allikmets et al. 1997; Shroyer et al. 2001), most of the studies reported no statistical significant association (Rivera et al. 2000; Souied et al. 2000; Guymer et al. 2001; Schmidt et al. 2003). In a similar way, we observed some marginal significant association with two variants at *CGREF1* and *APOE* variants with atrophic and mixed AMD forms. Addi-

tionally studies are needed with larger cohorts to confirm those observations.

We could not detect statistically significant association in our population between other minor susceptibility genes and advanced AMD, such as *CST3*, *CX3CR1*, *FBLN5*, *HMCN1*, *PON1*, *SOD2*, *TLR4*, *VEGFA* and *VLDLR*, in agreement with other reports (Schultz et al. 2003; Abecasis et al. 2004; Baird et al. 2004; Hayashi



et al. 2004; Bojanowski et al. 2005; Esfandiary et al. 2005; Schmidt et al. 2005; Fuse et al. 2006; Kaur et al. 2006; Seitsonen et al. 2006; Fisher et al. 2007; Richardson et al. 2007; Despriet et al. 2008; Edwards et al. 2008; Utheim et al. 2008). Discrepancies in replication of risk variants in association studies could be caused by population heterogeneity, disease heterogeneity, and/or the use of different diagnostic criteria among cases, but it could also reflect the lack of power to detect modest gene effects with under-sized samples. With our sample size, the study reached >80% power at a 5% significance level to detect an odds ratio greater than 1.52 when the allele frequency is 0.05, or an OR >1.26 for an allele at a frequency of 30%. Since we only examined for association advanced stages of AMD in our study, it could be possible that some of these candidate genes are only associated with the early forms of AMD.

Recently, other risk and protective variants on complement genes have been strongly associated with AMD; however, they could not be assessed here because the study design and genotyping were performed before the variants in these loci were confirmed as risk and protective factors.

In summary, we have replicated the CFH and *ARMS2* gene variants association with advanced AMD in the Spanish population. Moreover, as it was previously reported (Deangelis et al. 2008), both loci influence risk independently, giving support to different pathways implicated in the pathogenesis of the disease. No evidence for a role of other previously reported genes in the development of AMD was found. Nevertheless, more extended studies should be performed in order to role out the effect of these genes taking into account different groups of populations and possible interactions with other genetic or environmental factors. Finally, although we have identified a gene variant (rs6820411) within the downstream region of the *FGF2* locus, with a novel hypothetical role in the pathogenesis of AMD, we could not replicate our findings in a matched US American set of samples. Validation of the putative effect of this variant deserves further analysis in an extended group of late AMD patients

with European descent, well characterized in the different clinical forms of the disease.

## Acknowledgements

We greatly thank all the members of the Spanish multi-centre group of AMD: A.García Layana, Clínica Universitaria de Pamplona, Navarra; B. Pazos González, Instituto Gallego de Oftalmología, Santiago de Compostela; M. Díaz Llopis, Hospital Universitario la Fe, Valencia; C. Torrón, Hospital Universitario Miguel Servet, Zaragoza; R. Coco, IOBA, Valladolid; F. Martínez, Hospital Marques de Valdecilla, Santander; J. Arraiz, Instituto Clínico Quirúrgico de Oftalmología, Bilbao; J. M. Ruiz Moreno, Vissum Instituto Oftalmológico, Alicante; C. Desco Esteban, Fundación Oftalmológica del Mediterráneo, Valencia; E. Esteban, Hospital Virgen de la Macarena, Sevilla; M.S. Figueroa, Hospital Ramón y Cajal, Madrid; F. Gómez-Ulla, Hospital Clínico Universitario de Santiago de Compostela; J. Bañuela Bañuela, Hospital de Alcorcón, Madrid; B. Fernández-Vega Sanz, Instituto Oftalmológico Fernández Vega, Asturias; L. Arias, Hospital Universitario de Bellvitge, Barcelona; and J. Fernández Vigo, Facultad Medicina, Universidad de Extremadura.

This study was supported by grants from the Xunta de Galicia (PGI-DIT06PXIB208204PR), the Instituto de Salud Carlos III (EMER07/018), and National Institutes of Health, USA. The sponsor or funding organization had no role in the design or conduct of this research.

## References

Abecasis GR, Yashar BM, Zhao Y et al. (2004): Age-related macular degeneration: a high-resolution genome scan for susceptibility loci in a population enriched for late-stage disease. *Am J Hum Genet* **74**: 482–494.

Age-Related Eye Disease Study Research Group (2000): Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: age-Related Eye Disease Study Report Number 3. *Ophthalmology* **107**: 2224–2232.

Allikmets R, Shroyer NF, Singh N et al. (1997): Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. *Science* **277**: 1805–1807.

Baguma-Nibasheka M, Li AW & Murphy PR (2007): The fibroblast growth factor-2 antisense gene inhibits nuclear accumulation of FGF-2 and delays cell cycle progression in C6 glioma cells. *Mol Cell Endocrinol* **267**: 127–136.

Baird PN, Chu D, Guida E, Vu HT & Guymer R (2004): Association of the M55L and Q192R paraoxonase gene polymorphisms with age-related macular degeneration. *Am J Ophthalmol* **138**: 665–666.

Barral S, Francis PJ, Schultz DW et al. (2006): Expanded genome scan in extended families with age-related macular degeneration. *Invest Ophthalmol Vis Sci* **47**: 5453–9.

Barrett JC, Fry B, Maller J & Daly MJ (2005): Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* **21**: 263–265.

Bojanowski CM, Tuo J, Chew EY, Csaky KG & Chan CC (2005): Analysis of Hemicentin-1, hOgg1, and E-selectin single nucleotide polymorphisms in age-related macular degeneration. *Trans Am Ophthalmol Soc* **103**: 37–44. discussion 44–45.

Browning AC, Dua HS & Amoaku WM (2008): The effects of growth factors on the proliferation and in vitro angiogenesis of human macular inner choroidal endothelial cells. *Br J Ophthalmol* **92**: 1003–1008.

Cameron DJ, Yang Z, Gibbs D et al. (2007): HTRA1 variant confers similar risks to geographic atrophy and neovascular age-related macular degeneration. *Cell Cycle* **6**: 1122–1125.

Deangelis MM, Ji F, Adams S et al. (2008): Alleles in the HtrA serine peptidase 1 gene alter the risk of neovascular age-related macular degeneration. *Ophthalmology* **115**: 1209–1215.

Despriet DD, Bergen AA, Merriam JE et al. (2008): Comprehensive analysis of the candidate genes CCL2, CCR2, and TLR4 in age-related macular degeneration. *Invest Ophthalmol Vis Sci* **49**: 364–371.

Dewan A, Liu M, Hartman S et al. (2006): HTRA1 promoter polymorphism in wet age-related macular degeneration. *Science* **314**: 989–992.

Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C & Farrer LA (2005): Complement factor H polymorphism and age-related macular degeneration. *Science* **308**: 421–424.

Edwards AO, Chen D, Fridley BL et al. (2008): Toll-like receptor polymorphisms and age-related macular degeneration. *Invest Ophthalmol Vis Sci* **49**: 1652–1659.

Esfandiary H, Chakravarthy U, Patterson C, Young I & Hughes AE (2005): Association study of detoxification genes in age related macular degeneration. *Br J Ophthalmol* **89**: 470–474.

Fisher SA, Abecasis GR, Yashar BM et al. (2005): Meta-analysis of genome scans of age-related macular degeneration. *Hum Mol Genet* **14**: 2257–2264.

Fisher SA, Rivera A, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Rudolph G

- & Weber BH (2007): Case-control genetic association study of fibulin-6 (FBLN6 or HMCN1) variants in age-related macular degeneration (AMD). *Hum Mutat* **28**: 406–413.
- Francis PJ, Schultz DW, Hamon S, Ott J, Weleber RG & Klein ML (2007): Haplotypes in the complement factor H (CFH) gene: associations with drusen and advanced age-related macular degeneration. *PLoS ONE* **2**: e1197.
- Frank RN (1997): Growth factors in age-related macular degeneration: pathogenic and therapeutic implications. *Ophthalmic Res* **29**: 341–353.
- Friedman DS, O'Colmain BJ, Munoz B et al. (2004): Prevalence of age-related macular degeneration in the United States. *Arch Ophthalmol* **122**: 564–572.
- Fritsche LG, Loenhardt T, Janssen A, Fisher SA, Rivera A, Keilhauer CN & Weber BH (2008): Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. *Nat Genet* **40**: 892–896.
- de la Fuente M, Blanco MJ, Pazos B et al. (2007): Complement factor H. *Ophthalmology* **114**: 193.e1–193.e2.
- Fuse N, Miyazawa A, Mengkegale M, Yoshida M, Wakusawa R, Abe T & Tamai M (2006): Polymorphisms in Complement Factor H and Hemicentin-1 genes in a Japanese population with dry-type age-related macular degeneration. *Am J Ophthalmol* **142**: 1074–1076.
- Gabriel SB, Schaffner SF, Nguyen H et al. (2002): The structure of haplotype blocks in the human genome. *Science* **296**: 2225–2229.
- Gold B, Merriam JE, Zernant J et al. (2006): Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. *Nat Genet* **38**: 458–462.
- Guymer RH, Heon E, Lotery AJ et al. (2001): Variation of codons 1961 and 2177 of the Stargardt disease gene is not associated with age-related macular degeneration. *Arch Ophthalmol* **119**: 745–751.
- Hageman GS, Anderson DH, Johnson LV et al. (2005): A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. *Proc Natl Acad Sci USA* **102**: 7227–7232.
- Hageman GS, Hancox LS, Taiber AJ et al. (2006): Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. *Ann Med* **38**: 592–604.
- Hahn P, Qian Y, Dentchev T, Chen L, Beard J, Harris ZL & Dunaief JL (2004): Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. *Proc Natl Acad Sci USA* **101**: 13850–13855.
- HapMap CI (2003): The International HapMap Project. *Nature* **426**: 789–796.
- Hayashi M, Merriam JE, Klaver CC et al. (2004): Evaluation of the ARMD1 locus on 1q25-31 in patients with age-related maculopathy: genetic variation in laminin genes and in exon 104 of HEMICENTIN-1. *Ophthalmic Genet* **25**: 111–119.
- Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T & Chakravarthy U (2006): A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. *Nat Genet* **38**: 1173–1177.
- Jager RD, Mieler WF & Miller JW (2008): Age-related macular degeneration. *N Engl J Med* **358**: 2606–2617.
- Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE & Gorin MB (2005): Susceptibility genes for age-related maculopathy on chromosome 10q26. *Am J Hum Genet* **77**: 389–407.
- Jun G, Klein BE, Klein R et al. (2005): Genome-wide analyses demonstrate novel loci that predispose to drusen formation. *Invest Ophthalmol Vis Sci* **46**: 3081–3088.
- Kanda A, Chen W, Othman M et al. (2007): A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. *Proc Natl Acad Sci USA* **104**: 16227–16232.
- Kang HJ, Choi KO, Kim BD, Kim S & Kim YJ (2005): FESD: a Functional Element SNPs Database in human. *Nucleic Acids Res* **33**: D518–D522.
- Kaur I, Hussain A, Hussain N et al. (2006): Analysis of CFH, TLR4, and APOE polymorphism in India suggests the Tyr402His variant of CFH to be a global marker for age-related macular degeneration. *Invest Ophthalmol Vis Sci* **47**: 3729–3735.
- Klein RJ, Zeiss C, Chew EY et al. (2005): Complement factor H polymorphism in age-related macular degeneration. *Science* **308**: 385–389.
- Lambooi AC, van Wely KH, Lindenberg-Kortleve DJ, Kuijpers RW, Kliffen M & Mooy CM (2003): Insulin-like growth factor-I and its receptor in neovascular age-related macular degeneration. *Invest Ophthalmol Vis Sci* **44**: 2192–2198.
- van Leeuwen R, Klaver CC, Vingerling JR, Hofman A & de Jong PT (2003): The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. *Arch Ophthalmol* **121**: 519–526.
- Li M, Atmaca-Sonmez P & Othman M (2006): CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. *Nat Genet* **38**: 1049–1054.
- Majewski J, Schultz DW, Weleber RG et al. (2003): Age-related macular degeneration – a genome scan in extended families. *Am J Hum Genet* **73**: 540–550.
- Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ & Seddon JM (2007): Variation in complement factor 3 is associated with risk of age-related macular degeneration. *Nat Genet* **39**: 1200–1201.
- Martin G, Schlunck G, Hansen LL & Agostini HT (2004): Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium. *Graefes Arch Clin Exp Ophthalmol* **242**: 321–326.
- Morcillo-Suarez C, Alegre J, Sangros R et al. (2008): SNP analysis to results (SNPator): a web-based environment oriented to statistical genomics analyses upon SNP data. *Bioinformatics* **24**: 1643–1644.
- Mullins RF, Russell SR, Anderson DH & Hageman GS (2000): Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. *FASEB J* **14**: 835–846.
- Ogata N, Matsushima M, Takada Y et al. (1996): Expression of basic fibroblast growth factor mRNA in developing choroidal neovascularization. *Curr Eye Res* **15**: 1008–1018.
- Ormsby RJ, Ranganathan S, Tong JC et al. (2008): Functional and structural implications of the complement factor H Y402H polymorphism associated with age-related macular degeneration. *Invest Ophthalmol Vis Sci* **49**: 1763–1770.
- Rakic JM, Lambert V, Munaut C et al. (2003): Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization. *Invest Ophthalmol Vis Sci* **44**: 1732–1739.
- Recalde S, Fernandez-Robredo P, Altarriba M, Salinas-Alaman A & Garcia-Layana A (2008): Age-related macular degeneration genetics. *Ophthalmology* **115**: 916–916.
- Richardson AJ, Islam FM, Guymer RH, Cain M & Baird PN (2007): A tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration. *Mol Vis* **13**: 2148–2152.
- Rivera A, White K, Stohr H et al. (2000): A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene in Stargardt disease and age-related macular degeneration. *Am J Hum Genet* **67**: 800–813.
- Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T & Weber BH (2005): Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. *Hum Mol Genet* **14**: 3227–3236.
- Schmidt S, Postel EA, Agarwal A et al. (2003): Detailed analysis of allelic variation in the ABCA4 gene in age-related maculopathy. *Invest Ophthalmol Vis Sci* **44**: 2868–2875.
- Schmidt S, Haines JL, Postel EA, Agarwal A, Kwan SY, Gilbert JR, Pericak-Vance MA & Scott WK (2005): Joint effects of smoking history and APOE genotypes in age-related macular degeneration. *Mol Vis* **11**: 941–949.

- Schmidt S, Hauser MA, Scott WK et al. (2006): Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. *Am J Hum Genet* **78**: 852–864.
- Schultz DW, Klein ML, Humpert A, Majewski J, Schain M, Weleber RG, Ott J & Acott TS (2003): Lack of an association of apolipoprotein E gene polymorphisms with familial age-related macular degeneration. *Arch Ophthalmol* **121**: 679–683.
- Seddon JM, Ajani UA & Mitchell BD (1997): Familial aggregation of age-related maculopathy. *Am J Ophthalmol* **123**: 199–206.
- Seitsonen S, Lemmela S, Holopainen J et al. (2006): Analysis of variants in the complement factor H, the elongation of very long chain fatty acids-like 4 and the hemicentin 1 genes of age-related macular degeneration in the Finnish population. *Mol Vis* **12**: 796–801.
- Shroyer NF, Lewis RA, Yatsenko AN, Wensel TG & Lupski JR (2001): Cosegregation and functional analysis of mutant ABCR (ABCA4) alleles in families that manifest both Stargardt disease and age-related macular degeneration. *Hum Mol Genet* **10**: 2671–2678.
- Skerka C, Lauer N, Weinberger AA et al. (2007): Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. *Mol Immunol* **44**: 3398–3406.
- Souied EH, Ducroq D, Rozet JM et al. (2000): ABCR gene analysis in familial exudative age-related macular degeneration. *Invest Ophthalmol Vis Sci* **41**: 244–247.
- Swaroop A, Chew EY, Rickman CB & Abecasis GR (2009): Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. *Annu Rev Genomics Hum Genet* **10**: 19–43.
- Tanimoto S, Tamura H, Ue T, Yamane K, Maruyama H, Kawakami H & Kiuchi Y (2007): A polymorphism of LOC387715 gene is associated with age-related macular degeneration in the Japanese population. *Neurosci Lett* **414**: 71–74.
- Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I & Kelly SP (2005): Smoking and age-related macular degeneration: a review of association. *Eye* **19**: 935–944.
- Tobler AR, Short S, Andersen MR et al. (2005): The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. *J Biomol Tech* **16**: 398–406.
- Utheim OA, Ritland JS, Utheim TP, Espeseth T, Lydersen S, Rootwelt H, Semb SO & Elsas T (2008): Apolipoprotein E genotype and risk for development of cataract and age-related macular degeneration. *Acta Ophthalmol* **86**: 401–403.
- Weeks DE, Conley YP, Tsai HJ et al. (2004): Age-related maculopathy: a genomewide scan with continued evidence of susceptibility loci within the 1q31, 10q26, and 17q25 regions. *Am J Hum Genet* **75**: 174–189.
- Weger M, Renner W, Steinbrugger I et al. (2007): Association of the HTRA1 -625G > A promoter gene polymorphism with exudative age-related macular degeneration in a Central European population. *Mol Vis* **13**: 1274–1279.
- Yates JR, Sepp T, Matharu BK et al. (2007): Complement C3 variant and the risk of age-related macular degeneration. *N Engl J Med* **357**: 553–561.
- Yu J, Wiita P, Kawaguchi R, Honda J, Jorgensen A, Zhang K, Fischetti VA & Sun H (2007): Biochemical analysis of a common human polymorphism associated with age-related macular degeneration. *Biochemistry* **46**: 8451–8461.

Received on March 26th, 2010.  
Accepted on October 2nd, 2010.

*Correspondence:*  
María Brión, PhD  
Faculty of Medicine  
University of Santiago de Compostela  
San Francisco s/n  
5782 Santiago de Compostela  
Spain  
Tel: + 34 981582327  
Fax: + 34981580336  
Email: maria.brion@usc.es